RegOpsPro™

Medicines Export Guide™

Practical guidance for applying the Medicines Export Operating Model to real routes, parties, products, shipment decisions and governance evidence.

Open Export Professional WorkspaceView Export Operating Model™
Route assessmentAuthorityShipment controlGovernance

What this guide is for

Use this guide to understand the judgement behind each workspace stage. It helps quality, regulatory, RP, commercial and logistics teams build one defensible export route from initial proposal through dispatch, receipt and periodic review.

How to use it

Read the relevant guide stage before completing the workspace. Record the route-specific evidence and decisions in the workspace, then transfer approved outputs into your authorised QMS or controlled business system.

The export implementation sequence

The sequence is intentionally route-led. A later control cannot compensate for an undefined transaction, missing permission or unidentified party.

1. Define

Map the real transaction, route and destination requirements.

2. Verify

Confirm authority, parties, product and documentary evidence.

3. Execute

Authorise dispatch, control movement and manage exceptions.

4. Govern

Review performance, actions and continuing suitability.

1

Define the transaction

Start with the real commercial and physical route. Record the product, exporting entity, dispatch site, destination, consignee, brokers, Incoterms and transit points.

Responsibility matrix

For each handover, record who performs the activity, who reviews it, the evidence due, the deadline and the escalation contact. Include collection, loading, customs, monitoring and receipt. Record the Incoterm edition and precise named place. Assess EXW or FCA against the actual controls; neither label is a shipment approval.

Control point
Do not begin with a generic export procedure. The route map is the control boundary for every later decision.
2

Verify destination requirements

Confirm importer entitlement, product status, permits, certificates, labelling and restrictions using authoritative evidence or qualified local advice.

Permission and certificate check

Record what the destination authority requires for this product and recipient, how the evidence was verified, and any validity or quantity limits. Match certificates to their purpose and applicant eligibility. Keep unresolved requirements visible as dispatch stop conditions.

Control point
Customer confirmation supports the assessment but should not be the sole basis for a critical legal conclusion.
3

Confirm exporter authority

Map each UK activity and premises to the relevant WDA(H), manufacturer’s authorisation or other permission and make RP oversight visible.

Controlled products

Assess additional permissions where controlled-drug or other special rules apply. A WDA(H) alone does not establish that every required permission is held. Record relevant licence references, authorised quantities and validity, with the accountable reviewer’s conclusion.

Control point
A valid licence is not enough if the actual site, product category or activity falls outside its scope.
4

Qualify every party

Assess customers, brokers, carriers, warehouses and hubs for identity, authority, GDP capability, transparency, sanctions and diversion risk.

Customer-arranged collection

Confirm the collecting carrier, verified consignee and delivery address against the approved route. Independently confirm changes using established contacts. Define access to transport evidence and escalation before collection. An unfamiliar courier and unexplained delivery address require investigation.

Control point
Approval must cover the exact party and role used, with restrictions and requalification triggers recorded.
5

Approve product eligibility

Check the actual product and batch for release status, recall or shortage restrictions, pack suitability, shelf life and destination conditions.

Dated restriction assessment

Check the current DHSC list and its scope before export. Record the product match and decision. Where an exception is used, retain its guidance basis and supporting transaction evidence; do not assume overseas supply automatically qualifies. Recheck after material order or rule changes.

Control point
Link the decision to the stock selected for export; do not rely on a general product approval.
6

Control dispatch and receipt

Reconcile product, batch, quantity, permits, certificates, carrier, route, security, temperature and dispatch authority before release.

Two separate evidence checks

Track delivery and proof of export separately. Reconcile agent instructions and returned records against the consignment. Record declaration references, departure evidence and any follow-up. Use current HMRC instructions for the applicable route; do not close an evidence gap merely because delivery was signed.

Control point
Retain custody, monitoring, proof-of-delivery and quantity-reconciliation evidence as one shipment pack.
7

Control exceptions

Contain customs delay, route deviation, loss, damage, excursion, rejection or return; establish location and status before disposition.

Delay and return decisions

Before qualified packaging duration is exceeded, arrange approved contingency storage and preserve monitoring data. Hold stock with uncertain exposure or custody pending product-specific assessment. Check the lawful return or re-import route separately from whether the goods may re-enter saleable stock.

Control point
Commercial urgency must not override product-status control, quality assessment, notification or security decisions.
8

Govern the portfolio

Review destinations, route risk, expiring permissions, party performance, exceptions, overdue actions and effectiveness.

Evidence-led oversight

Trend overdue export documents, address changes, courier substitutions, restrictions and temperature events. Assign source-review ownership and respond to rule changes. Sample complete consignment trails to test whether revised controls work in practice.

Control point
Use trends to suspend weak routes, improve controls and make material export risk visible to the RP and senior management.

Sources and route boundaries

This model supports human-medicines export assessment. Record origin, destination and transit jurisdictions, including any Great Britain or Northern Ireland differences. Import assurance remains in the RP-I model; unlicensed-medicines supply needs its own assessment.

Sources checked 21 September 2026. Inspector blogs explain practical expectations at their publication date. Industry commentary is supporting reading. Use current official guidance and destination evidence for each decision. Worked scenarios are illustrative RegOpsPro examples.

View the export source coverage register for scope, dates and knowledge-search availability.

Working-workspace boundary. RegOpsPro supports assessment, evidence organisation and decision preparation. It does not replace applicable law, destination-country advice, the Responsible Person, controlled procedures, formal approvals or records held in your organisation’s authorised QMS.

Move from guidance to execution

Use the workspace to capture the route, evidence, decisions, owners and actions for review.

Open Export Professional WorkspaceBack to Export Model™View Toolkits